GC
NVCR icon

Guggenheim Capital’s NovoCure NVCR Stock Holding History

Guggenheim Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-123,949
Closed -$1.85M – 1921
2023
Q4 		$1.85M Buy
123,949
+106,452
+608% +$1.42M 0.01% 874
2023
Q3 		$283K Sell
17,497
-371
-2% -$10.7K ﹤0.01% 1645
2023
Q2 		$742K Sell
17,868
-332
-2% -$20.6K 0.01% 1301
2023
Q1 		$1.09M Sell
18,200
-252
-1% -$20.1K 0.01% 1135
2022
Q4 		$1.35M Sell
18,452
-1,723
-9% -$130K 0.01% 1023
2022
Q3 		$1.53M Buy
20,175
+3,132
+18% +$244K 0.01% 950
2022
Q2 		$1.18M Buy
17,043
+2,629
+18% +$198K 0.01% 1152
2022
Q1 		$1.19M Buy
+14,414
New +$1.06M 0.01% 1266
2021
Q4 		– Sell
-27,658
Closed -$3.21M – 2188
2021
Q3 		$3.21M Buy
27,658
+11,781
+74% +$1.78M 0.02% 836
2021
Q2 		$3.52M Sell
15,877
-8,670
-35% -$1.69M 0.02% 811
2021
Q1 		$3.25M Buy
24,547
+2,310
+10% +$365K 0.02% 805
2020
Q4 		$3.85M Sell
22,237
-2,185
-9% -$299K 0.02% 702
2020
Q3 		$2.72M Sell
24,422
-42,079
-63% -$3.36M 0.02% 764
2020
Q2 		$3.94M Buy
+66,501
New +$4.37M 0.03% 613
2020
Q1 		– Sell
-4,592
Closed -$387K – 1953
2019
Q4 		$387K Buy
+4,592
New +$371K ﹤0.01% 1704
2018
Q4 		– Sell
-4,454
Closed -$233K – 2307
2018
Q3 		$233K Buy
+4,454
New +$177K ﹤0.01% 2294

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Guggenheim Capital's NVCR Position: Q1 2024 in Review

Guggenheim Capital sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 123,949 shares — an estimated $1.85M sold.

Guggenheim Capital first reported a position in NVCR in Q3 2018 and held it in 16 quarters. The position peaked at $3.94M in Q2 2020. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • Guggenheim Capital reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
  • Guggenheim Capital sold 123,949 NovoCure shares in Q1 2024, an estimated $1.85M.
  • Guggenheim Capital first reported a position in NovoCure in Q3 2018 and held it in 16 quarters.
  • Guggenheim Capital's NovoCure position peaked at $3.94M in Q2 2020.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Guggenheim Capital's 13F filing for Q1 2024, filed 14 May 2024.